Gattefossé Pharmaceuticals

Discover our last interview given by Alexandre Gil, Group Director for Pharmaceuticals, in Pharma Industrial India. In this interview, we discuss the unique advantages of Gattefossé excipients, the personalized medicine trend, our current R&D focus areas and our ambition for the Indian market. To read the full interview: https://lnkd.in/ddU5uw-Z #gattefossé #pharmaceuticals #india

Unlocking the power of lipids in hot-melt extrusion (HME)! 🔩 HME is transforming drug formulation by improving the bioavailability of poorly soluble active pharmaceutical ingredients (APIs). It is a well-known technique to produce amorphous solid dispersions (ASD), in which APIs are dispersed in an amorphous polymer matrix, preventing crystallization and enhancing dissolution rates. Lipid-based excipients can act as plasticizers, reducing the polymer’s glass transition temperature and the process’ energy consumption, making it adapted for heat-sensitive APIs. We also demonstrated that our Gelucire® and Compritol® 888 ATO could accelerate drug release and stabilize ASDs. Discover how our excipients can enhance your HME processes! ⬇️ For more information read our dedicated article and case studies: https://lnkd.in/dGSGxjug #gattefossé #pharmaceuticals #hotmeltextrusion

Gattefossé offers a highly versatile range of excipients to address different formulation challenges! Our Gelucire® product line is available in different grades, each with unique characteristics and functionalities! 🔹 Gelucire® 59/14: a water-dispersible surfactant for enhanced solubility and bioavailability of lipophilic API. Perfect for a self-emulsifying drug delivery system via manufacturing processes such as capsule filling, hot melt extrusion, melt granulation, and 3D printing. 🔹 Gelucire® 48/16: a water-soluble surfactant for enhanced solubility and bioavailability of lipophilic API. It spontaneously forms a micellar solution in aqueous media, and can be used in processes such as capsule filling, melt granulation, and hot melt extrusion. 🔹 Gelucire® 43/01: a hard fat composed primarily of triglycerides of saturated fatty acids, it functions as an oily vehicle and suspending agent. Like other Gelucire® grades, it is suitable for processes such as capsule filling, melt granulation, and hot melt extrusion. If you are interested in trying our Gelucire® products in your formulation and want additional information, contact your Gattefossé representative. #gattefossé #pharmaceuticals

From November 26th to 28th, 2024, Gattefossé India participated in CPHI & PMEC India , held at the India Expo Centre in Greater Noida, Delhi NCR. As part of the event’s key moments, Dr. Sunil represented Gattefossé in the prestigious forum & shared his perspectives & insights in round table discussion entitled "Seizing New Frontiers: Uncloking India's Potential Amidst Global Shifts". This gathering provided an excellent opportunity to exchange insights, strengthen connections, and explore collaborative opportunities within the pharmaceutical industry. Thank you to all the participants and visitors who made this event meaningful and impactful. #CPHI2024 #Gattefossé #PharmaIndustry

🎉 Happy New Year 2025! 🎉 The entire team at Gattefossé Pharmaceuticals wishes you a year full of success, adventures, and unforgettable moments. Thank you for being part of our journey, and we look forward to more exciting projects together. #gattefossé #pharmaceuticals #2025

🎉 2024, what a year! 🎉 Take a look back at our year 2024 👀 and see you in 2025! #gattefossé #pharmaceuticals

A busy November month for our Gattefossé Asia Pacific Affiliate! On November 14th, our colleagues held a technical seminar in East Java and attracted nearly 50 researchers from universities and pharmaceutical companies. They addressed the use of lipid-based excipients for oral bioavailability enhancement, sustained release, lubrication, topical and transdermal applications. They had the privilege of collaborating with Dr Woo-Heon Song, an experienced pharmaceutical consultant from South Korea, who presented powder compaction analysis and demonstrated the benefits of Compritol® 888 ATO and Precirol® ATO 5 as lubricants. Then, from November 26th to 28th, we participated in the Annual Meeting and International Conference of the Korean Society of Pharmaceutical Science and technology in Seoul, where we hosted a booth exhibition and showcased our range of functional excipients to improve oral drug bioavailability. About 500 pharmaceutical R&D formulators, university professors and PhD students participated. We received many inquiries from researchers interested in permeation enhancement of peptides and large molecules. See you in 2025 for more events! #gattefossé #pharmaceuticals # asiapacific

🌟Exciting new insights on Gelucire® and its role in bioavailability enhancement! In this new article published by the University of Bologna (Italy), the researchers studied the impact of different concentrations of Gelucire® on ketoprofen amorphous and crystalline solubility. Results indicate that with the use of Gelucire® at concentrations above 50 µg/mL, the crystalline and amorphous solubilities of ketoprofen gradually increased. Furthermore, the Gelucire® micelles inhibit ketoprofen recrystallization from the supersaturated solution for over 6 hours! Access the full publication here: https://lnkd.in/dCCmjzaN #gattefossé #pharmaceuticals #gelucire

🐶 We are pleased to introduce you to our newest digital brochure on the topic of veterinary medicines! This interactive document will walk you through our wide offer of lipid-based excipients for oral, topical/transdermal and injectable routes for both companion and food-producing animals. 📃Download our brochure here: https://lnkd.in/dDrBV5iA 🖥️ Wanting more information? Access our dedicated webinar series here: https://lnkd.in/d_UrcAGE Or contact us here: https://lnkd.in/d3NicfHw #gattefossé #animalhealth #brochure

Last month, Gattefossé Brazil participated in the VII ABCF Congress in Florianópolis, Brazil - the Congress of the Brazilian Pharmaceutical Sciences Association. During the event, showcasing strong lab teamwork from our headquarters, Paulo Cunha, Technical Coordinator Pharmaceuticals - South and Central America, presented a poster entitled "Bigels: Case Studies of an Innovative Topical Dosage Form." The poster introduced the concept of developing more user-friendly and acceptable pharmaceutical topical formulations, presenting three different textures and formulations of bigels to the evaluators and audience. Check out the poster below! Additionally, at the congress, Kelly Bueno, MSc./MBA, Business Development Pharmaceutical Manager - South and Central America, delivered a talk on the development and scale-up of nano drug delivery systems, which was attended by a full house! This participation and these presentations demonstrate Gattefossé's global commitment to advancing science! #Gattefossé #PharmaceuticalSciences #Congress